CureVac (CVAC) Competitors $5.41 +0.02 (+0.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.40 -0.02 (-0.28%) As of 08/1/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. TLX, PCVX, MRUS, CYTK, RNA, ADMA, KRYS, MTSR, ABVX, and ZLABShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), Merus (MRUS), Cytokinetics (CYTK), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Metsera (MTSR), Abivax (ABVX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Its Competitors Telix Pharmaceuticals Vaxcyte Merus Cytokinetics Avidity Biosciences ADMA Biologics Krystal Biotech Metsera Abivax Zai Lab Telix Pharmaceuticals (NASDAQ:TLX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Which has stronger earnings & valuation, TLX or CVAC? CureVac has higher revenue and earnings than Telix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M8.55$32.93MN/AN/ACureVac$579.18M2.10$175.50M$0.925.88 Do institutionals and insiders believe in TLX or CVAC? 17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is TLX or CVAC more profitable? CureVac has a net margin of 35.44% compared to Telix Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of 30.89% beat Telix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A CureVac 35.44%30.89%25.54% Do analysts prefer TLX or CVAC? Telix Pharmaceuticals currently has a consensus price target of $22.33, indicating a potential upside of 71.14%. CureVac has a consensus price target of $6.83, indicating a potential upside of 26.31%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Telix Pharmaceuticals is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer TLX or CVAC? In the previous week, Telix Pharmaceuticals had 9 more articles in the media than CureVac. MarketBeat recorded 9 mentions for Telix Pharmaceuticals and 0 mentions for CureVac. CureVac's average media sentiment score of 1.79 beat Telix Pharmaceuticals' score of 0.00 indicating that CureVac is being referred to more favorably in the news media. Company Overall Sentiment Telix Pharmaceuticals Neutral CureVac Very Positive SummaryCureVac beats Telix Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio5.8817.6228.6723.80Price / Sales2.10179.18373.9066.58Price / Cash6.1741.9535.4557.96Price / Book1.618.508.275.55Net Income$175.50M-$55.06M$3.24B$259.03M7 Day Performance-0.92%-3.98%-3.69%-4.59%1 Month Performance0.19%9.59%4.33%4.46%1 Year Performance56.81%6.72%25.95%18.03% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac3.5998 of 5 stars$5.41+0.4%$6.83+26.3%+51.1%$1.21B$579.18M5.88880News CoveragePositive NewsTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.81B$516.72M0.00N/AGap DownPCVXVaxcyte2.2389 of 5 stars$35.87-2.1%$136.50+280.5%-58.0%$4.73BN/A0.00160News CoveragePositive NewsUpcoming EarningsMRUSMerus2.9208 of 5 stars$65.59-1.8%$86.40+31.7%+25.1%$4.62B$36.13M0.0037News CoverageCYTKCytokinetics4.0154 of 5 stars$36.63-1.5%$70.92+93.6%-36.6%$4.44B$18.47M-6.92250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeRNAAvidity Biosciences2.7815 of 5 stars$34.56-4.7%$66.35+92.0%-19.4%$4.37B$10.90M-11.52190News CoverageUpcoming EarningsADMAADMA Biologics4.2926 of 5 stars$18.00-0.1%$27.67+53.7%+57.7%$4.30B$426.45M32.16530Upcoming EarningsKRYSKrystal Biotech4.8885 of 5 stars$152.91+3.6%$211.33+38.2%-21.0%$4.27B$290.52M32.88210Upcoming EarningsMTSRMetseraN/A$39.43-2.6%$55.00+39.5%N/A$4.25BN/A0.0081News CoverageEarnings ReportLockup ExpirationAnalyst RevisionGap UpABVXAbivax3.6107 of 5 stars$66.57+0.1%$80.00+20.2%+511.7%$4.22BN/A0.0061News CoverageAnalyst ForecastGap DownZLABZai Lab2.217 of 5 stars$38.69+4.1%$54.28+40.3%+99.7%$4.13B$398.99M0.001,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies TLX Competitors PCVX Competitors MRUS Competitors CYTK Competitors RNA Competitors ADMA Competitors KRYS Competitors MTSR Competitors ABVX Competitors ZLAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
